E-LIB Suche - Ergebnisse für: Asselah, T.

1

Adjusted estimate of the prevalence of hepatitis delta viru..:

Razavi-Shearer, D. ; Child, H. ; Razavi-Shearer, K....
Journal of Hepatology. 80 (2024) 2 - p. 232-242 , 2024

Link: https://doi.org/10.1016/..

2

Bulevirtide monotherapy is safe and well tolerated in patie..:

Asselah, T. ; Lampertico, P. ; Aleman, S....
Digestive and Liver Disease. 55 (2023) - p. S74 , 2023

Link: https://doi.org/10.1016/..

3

Hépatite Delta : épidémiologie, diagnostic, histoire nature..:

Loureiro, D. ; Castelnau, C. ; Bed, C.M..
La Revue de Médecine Interne. 43 (2022) 3 - p. 160-169 , 2022

Link: https://doi.org/10.1016/..

4

Pretherapeutic Evaluation of the Patients with HCV Infectio:

, In: Viral Hepatitis: Chronic Hepatitis C,

Asselah, T. ; Salmon-Ceron, Dominique - p. 59-64 , 2019

Link: https://doi.org/10.1007/..

5

Cover Image:

Camus, G. ; Han, B. ; Asselah, T....
Journal of Viral Hepatitis. 25 (2018) 2 - p. , 2018

Link: https://doi.org/10.1111/..

6

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients..:

Asselah, T. ; Tran, T. ; Alves, K....
Journal of Hepatology. 68 (2018) - p. S39 , 2018

Link: https://doi.org/10.1016/..

7

High efficacy and safety of grazoprevir and elbasvir for 8 ..:

Abergel, A. ; Hezode, C. ; Asselah, T....
Journal of Hepatology. 68 (2018) - p. S110 , 2018

Link: https://doi.org/10.1016/..

8

Efficacy and safety of 8 weeks of elbasvir/grazoprevir in H..:

Asselah, T. ; Pol, S. ; Hezode, C....
Journal of Hepatology. 68 (2018) - p. S3-S4 , 2018

Link: https://doi.org/10.1016/..

9

Glecaprevir/pibrentasvir in patients with hepatitis C and p..:

Poordad, F. ; Zeuzem, S. ; Asatryan, A....
Journal of Hepatology. 68 (2018) - p. S262 , 2018

Link: https://doi.org/10.1016/..

10

The impact of direct antiviral agent therapy on liver fibro..:

Kutala, B. ; Darrigrand, N.B. ; Corinne, C....
Journal of Hepatology. 68 (2018) - p. S541 , 2018

Link: https://doi.org/10.1016/..

11

High efficacy is accompanied with substantial gains in pati..:

Younossi, Z.M. ; Stepanova, M. ; Jacobson, I....
Journal of Hepatology. 66 (2017) 1 - p. S114 , 2017

Link: https://doi.org/10.1016/..

12

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvi..:

Foster, G.R. ; Gane, E. ; Asatryan, A....
Journal of Hepatology. 66 (2017) 1 - p. S33 , 2017

Link: https://doi.org/10.1016/..

13

Value Of Treating All Liver Fibrosis Stages To Reach Elimin..:

Tanguy Melac, A ; Asselah, T ; Ethgen, O...
Value in Health. 20 (2017) 9 - p. A798 , 2017

Link: https://doi.org/10.1016/..

14

Sofosbuvir and velpatasvir with or without voxilaprevir in ..:

Younossi, Z. M. ; Stepanova, M. ; Jacobson, I. M....
Alimentary Pharmacology & Therapeutics. 47 (2017) 2 - p. 259-267 , 2017

Link: https://doi.org/10.1111/..

15

Resistance characterization of ledipasvir and velpatasvir i..:

Camus, G. ; Han, B. ; Asselah, T....
Journal of Viral Hepatitis. 25 (2017) 2 - p. 134-143 , 2017

Link: https://doi.org/10.1111/..